已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial

特立帕肽 德诺苏马布 医学 绝经后骨质疏松症 骨矿物 骨质疏松症 绝经后妇女 随机对照试验 内科学 肿瘤科
作者
Joy N. Tsai,Hang Lee,Natalie L. David,Richard Eastell,Benjamin Z. Leder
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:7 (10): 767-775 被引量:60
标识
DOI:10.1016/s2213-8587(19)30255-4
摘要

In the Denosumab and Teriparatide Administration (DATA) study, we showed that denosumab fully inhibits teriparatide-induced bone resorption while allowing for continued teriparatide-induced bone formation, resulting in larger increases in hip and spine bone mineral density (BMD) than with either drug alone. We aimed to assess whether administration of denosumab with high dose teriparatide would stimulate larger increases in bone mass than those observed in the DATA study.DATA-HD was an open-label, randomised, controlled phase 4 trial done at Massachusetts General Hospital. Eligible women were postmenopausal women (at least 36 months since last menses or since hysterectomy with a follicle-stimulating hormone concentration of ≥40 U/L) with osteoporosis. Participants were randomly assigned (1:1) to receive teriparatide 20 μg (standard dose) or 40 μg (high dose) daily via subcutaneous injection for 9 months. At 3 months, both groups were started on denosumab 60 mg every 6 months via subcutaneous injection for 12 months. Areal BMD (aBMD) was measured at 0, 3, 9, and 15 months. Treatment was given open label, but outcome assessors were masked. The primary endpoint was percentage change from baseline in spine areal BMD (aBMD) at 15 months. Women who completed at least one study visit after baseline were included in the modified intention-to-treat analysis. Safety was assessed in all randomly assigned participants. This study is registered with ClinicalTrials.gov, number NCT02176382.Between Oct 15, 2014, and June 10, 2016, 269 women were assessed for eligibility. 76 participants were randomly assigned to 20 μg teriparatide (n=39) or 40 μg teriparatide (n=37), of whom 69 completed at least one post-baseline visit. At 15 months, mean spine aBMD had increased to a significantly greater extent in the 40 μg group (17·5% [SD 6·0] increase) than the 20 μg group (9·5% [3·2]; difference 8·1%, 95% CI 5·5 to 10·6, p<0·0001). Mean femoral neck aBMD had also increased to a greater extent in the 40 μg group (6·8% [SD 4·1] increase) than the 20 μg group (4·3% [3·7]; difference 2·5%, 0·5 to 4·5, p=0·04), as did mean total hip aBMD (40 μg group, 6·1% [3·4] increase; 20 μg group, 3·9% [2·9] increase; difference 2·2%, 0·6 to 3·8, p<0·0001). 30 (77%) of 39 participants in the 20 μg group and 29 (78%) of 37 participants in the 40 μg group had an adverse event, and seven (18%) and two (5%) patients had serious adverse events. The most frequent adverse events were joint pain (15 [38%]), muscle cramp (15 [38%]), and fatigue (12 [31%]) in the 20 μg group group and fatigue (14 [38%]), nausea (16 [43%]), and joint pain (17 [46%]) in the 40 μg group. No deaths were reported.Combined treatment with teriparatide 40 μg and denosumab increases spine and hip BMD more than standard combination therapy. This large and rapid increase in bone mass suggest that this high dose regimen might provide a method of restoring skeletal integrity in patients with osteoporosis.National Institutes of Health and the Dart Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yyc完成签到,获得积分10
1秒前
Niercol完成签到,获得积分10
5秒前
walalalla完成签到,获得积分10
6秒前
lzt完成签到 ,获得积分10
7秒前
8秒前
Joaquin完成签到 ,获得积分10
10秒前
Yn_发布了新的文献求助10
13秒前
15秒前
白开水完成签到 ,获得积分10
19秒前
细斟北斗完成签到,获得积分10
21秒前
LiuXiaocui发布了新的文献求助10
22秒前
如约而至完成签到 ,获得积分10
24秒前
小名余土土完成签到 ,获得积分10
24秒前
小鱼完成签到 ,获得积分10
27秒前
乐乐应助几酝采纳,获得10
28秒前
33秒前
35秒前
mawanyu完成签到 ,获得积分10
36秒前
37秒前
zzyl发布了新的文献求助10
38秒前
39秒前
41秒前
小鲤鱼完成签到 ,获得积分10
42秒前
田一点完成签到,获得积分10
42秒前
潘善若发布了新的文献求助10
43秒前
Li发布了新的文献求助10
44秒前
44秒前
狂野的含烟完成签到 ,获得积分10
44秒前
45秒前
123完成签到 ,获得积分10
45秒前
少年完成签到,获得积分10
46秒前
鸽子爱好者完成签到,获得积分10
48秒前
大力的宝川完成签到 ,获得积分10
49秒前
LEMONS完成签到 ,获得积分10
50秒前
研友_VZG7GZ应助潘善若采纳,获得10
51秒前
Grandir发布了新的文献求助20
51秒前
今后应助科研通管家采纳,获得10
52秒前
田様应助科研通管家采纳,获得10
52秒前
我是老大应助科研通管家采纳,获得10
52秒前
科研通AI5应助科研通管家采纳,获得10
52秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989949
求助须知:如何正确求助?哪些是违规求助? 3532017
关于积分的说明 11255865
捐赠科研通 3270829
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882233
科研通“疑难数据库(出版商)”最低求助积分说明 809216